Ceftriaxone Therapy of Bacterial Meningitis in Children

Twenty-nine children, age 3 months to 11 years, admitted with the clinical diagnosis of bacterial meningitis to the Department of Child Health, were included in a prospective treatment study of ceftriaxone (RocephinHoffmann- La Roche AG Bas/e, Switzerland). Ceftriaxone was used as the only antibioti...

Full description

Bibliographic Details
Main Authors: Sumarmo Sumarmo, S. R. Harun, M. A. Nathin
Format: Article
Language:English
Published: Indonesian Pediatric Society Publishing House 2019-07-01
Series:Paediatrica Indonesiana
Subjects:
Online Access:https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2249
id doaj-0b6aa64c708c44e39e0070d1fed375ed
record_format Article
spelling doaj-0b6aa64c708c44e39e0070d1fed375ed2020-11-25T01:49:09ZengIndonesian Pediatric Society Publishing HousePaediatrica Indonesiana0030-93112338-476X2019-07-01287-8141710.14238/pi28.7-8.1988.141-72249Ceftriaxone Therapy of Bacterial Meningitis in ChildrenSumarmo Sumarmo0S. R. Harun1M. A. Nathin2Department of Child Health, Universitas Indonesia Medical School/Dr. Cipto Mangunkusumo Hospital, JakartaDepartment of Child Health, Universitas Indonesia Medical School/Dr. Cipto Mangunkusumo Hospital, JakartaDepartment of Child Health, Universitas Indonesia Medical School/Dr. Cipto Mangunkusumo Hospital, JakartaTwenty-nine children, age 3 months to 11 years, admitted with the clinical diagnosis of bacterial meningitis to the Department of Child Health, were included in a prospective treatment study of ceftriaxone (RocephinHoffmann- La Roche AG Bas/e, Switzerland). Ceftriaxone was used as the only antibiotic agent in single daily dose of 100 mg/kg body weight given intravenously for a minimum of 10 days. Of these 29 patients, 25 (86.2%) recovered, 3 (10.3%) died and 1 (3.4%) no respond to treatment. Among fatal cases, two patients had subdural empyema and one had a cerebral abscess. The microorganisms isolated from cerebrospinal fluid were: Streptococcus pneumoniae (5), Pseudomonas sp. (4), Proteus sp. (2), Salmonella typhi (1), Escherichia coli (1), Clostridium sp. (1), Pseudomonas aeruginosa (1), Staphylococcus aureus {1), and Streptococcus haemolyticus (1). In 12 patients (41,4%), organisms were not identified. The diagnosis was made based on clinical symptoms, Gram staining, cell count. ~!·tease, and protein in the CSF. In all patients, repeated spinal fluid cultures had no bacterial growth at 24 hours after initation of intravenous therapy. No evidence of clinical important drug toxicity was observed. Three p'Oiients, however, had lightly elevated hepatic transaminase levels, and one patient had rnild neutropenia. These clinical and bacteriological results suggested that ceftriaxone is reasonably safe and effective in the treatment of bacterial meningitis caused by the most common pediatric pathogens in Indonesian children over one month of age.https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2249ceftriaxone; bacterial meningitis; antibiotic; subdural empyema; cerebral abscess
collection DOAJ
language English
format Article
sources DOAJ
author Sumarmo Sumarmo
S. R. Harun
M. A. Nathin
spellingShingle Sumarmo Sumarmo
S. R. Harun
M. A. Nathin
Ceftriaxone Therapy of Bacterial Meningitis in Children
Paediatrica Indonesiana
ceftriaxone; bacterial meningitis; antibiotic; subdural empyema; cerebral abscess
author_facet Sumarmo Sumarmo
S. R. Harun
M. A. Nathin
author_sort Sumarmo Sumarmo
title Ceftriaxone Therapy of Bacterial Meningitis in Children
title_short Ceftriaxone Therapy of Bacterial Meningitis in Children
title_full Ceftriaxone Therapy of Bacterial Meningitis in Children
title_fullStr Ceftriaxone Therapy of Bacterial Meningitis in Children
title_full_unstemmed Ceftriaxone Therapy of Bacterial Meningitis in Children
title_sort ceftriaxone therapy of bacterial meningitis in children
publisher Indonesian Pediatric Society Publishing House
series Paediatrica Indonesiana
issn 0030-9311
2338-476X
publishDate 2019-07-01
description Twenty-nine children, age 3 months to 11 years, admitted with the clinical diagnosis of bacterial meningitis to the Department of Child Health, were included in a prospective treatment study of ceftriaxone (RocephinHoffmann- La Roche AG Bas/e, Switzerland). Ceftriaxone was used as the only antibiotic agent in single daily dose of 100 mg/kg body weight given intravenously for a minimum of 10 days. Of these 29 patients, 25 (86.2%) recovered, 3 (10.3%) died and 1 (3.4%) no respond to treatment. Among fatal cases, two patients had subdural empyema and one had a cerebral abscess. The microorganisms isolated from cerebrospinal fluid were: Streptococcus pneumoniae (5), Pseudomonas sp. (4), Proteus sp. (2), Salmonella typhi (1), Escherichia coli (1), Clostridium sp. (1), Pseudomonas aeruginosa (1), Staphylococcus aureus {1), and Streptococcus haemolyticus (1). In 12 patients (41,4%), organisms were not identified. The diagnosis was made based on clinical symptoms, Gram staining, cell count. ~!·tease, and protein in the CSF. In all patients, repeated spinal fluid cultures had no bacterial growth at 24 hours after initation of intravenous therapy. No evidence of clinical important drug toxicity was observed. Three p'Oiients, however, had lightly elevated hepatic transaminase levels, and one patient had rnild neutropenia. These clinical and bacteriological results suggested that ceftriaxone is reasonably safe and effective in the treatment of bacterial meningitis caused by the most common pediatric pathogens in Indonesian children over one month of age.
topic ceftriaxone; bacterial meningitis; antibiotic; subdural empyema; cerebral abscess
url https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2249
work_keys_str_mv AT sumarmosumarmo ceftriaxonetherapyofbacterialmeningitisinchildren
AT srharun ceftriaxonetherapyofbacterialmeningitisinchildren
AT manathin ceftriaxonetherapyofbacterialmeningitisinchildren
_version_ 1725008610631614464